1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Endothelial Dysfunction - Pipeline Review, H2 2014

Endothelial Dysfunction - Pipeline Review, H2 2014

  • November 2014
  • -
  • Global Markets Direct
  • -
  • 32 pages

Endothelial Dysfunction - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Endothelial Dysfunction - Pipeline Review, H2 2014’, provides an overview of the Endothelial Dysfunction’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Endothelial Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endothelial Dysfunction and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Endothelial Dysfunction
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Endothelial Dysfunction and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Endothelial Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Endothelial Dysfunction pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Endothelial Dysfunction
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Endothelial Dysfunction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Endothelial Dysfunction - Pipeline Review, H2 2014
Table of Contents

Introduction 5
Global Markets Direct Report Coverage 5
Endothelial Dysfunction Overview 6
Therapeutics Development 7
Pipeline Products for Endothelial Dysfunction - Overview 7
Pipeline Products for Endothelial Dysfunction - Comparative Analysis 8
Endothelial Dysfunction - Therapeutics under Development by Companies 9
Endothelial Dysfunction - Therapeutics under Investigation by Universities/Institutes 10
Endothelial Dysfunction - Pipeline Products Glance 11
Early Stage Products 11
Endothelial Dysfunction - Products under Development by Companies 12
Endothelial Dysfunction - Products under Investigation by Universities/Institutes 13
Endothelial Dysfunction - Companies Involved in Therapeutics Development 14
Chugai Pharmaceutical Co., Ltd. 14
Glucox Biotech AB 15
Johnson and Johnson 16
Endothelial Dysfunction - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Molecule Type 22
Drug Profiles 24
Gene Therapy for Arteriosclerosis and Endothelial Dysfunction - Drug Profile 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
maxacalcitol - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
OX-029 - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
Small Molecule to Activate HO-1 for Endothelial Dysfunction - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
Small Molecule to Inhibit NOX-4 for Endothelial Dysfunction - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Endothelial Dysfunction - Dormant Projects 29
Endothelial Dysfunction - Discontinued Products 30
Appendix 31
Methodology 31
Coverage 31
Secondary Research 31
Primary Research 31
Expert Panel Validation 31
Contact Us 32
Disclaimer 32

List of Tables

Number of Products under Development for Endothelial Dysfunction, H2 2014 7
Number of Products under Development for Endothelial Dysfunction - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Early Stage Development, H2 2014 11
Products under Development by Companies, H2 2014 12
Products under Investigation by Universities/Institutes, H2 2014 13
Endothelial Dysfunction - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2014 14
Endothelial Dysfunction - Pipeline by Glucox Biotech AB, H2 2014 15
Endothelial Dysfunction - Pipeline by Johnson and Johnson, H2 2014 16
Assessment by Monotherapy Products, H2 2014 17
Number of Products by Stage and Target, H2 2014 19
Number of Products by Stage and Mechanism of Action, H2 2014 21
Number of Products by Stage and Molecule Type, H2 2014 23
Endothelial Dysfunction - Dormant Projects, H2 2014 29
Endothelial Dysfunction - Discontinued Products, H2 2014 30

List of Figures

Number of Products under Development for Endothelial Dysfunction, H2 2014 7
Number of Products under Development for Endothelial Dysfunction - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Early Stage Products, H2 2014 11
Assessment by Monotherapy Products, H2 2014 17
Number of Products by Top 10 Targets, H2 2014 18
Number of Products by Stage and Top 10 Targets, H2 2014 19
Number of Products by Top 10 Mechanism of Actions, H2 2014 20
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 21
Number of Products by Top 10 Molecule Types, H2 2014 22
Number of Products by Stage and Top 10 Molecule Types, H2 2014 23

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth

Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth

  • $ 4995
  • Industry report
  • October 2016
  • by GBI Research

Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth Summary Cardiovascular disease (CVD) covers a range of difference ...

Chronic Heart Failure - Market Insights, Epidemiology and Market Forecast-2023

Chronic Heart Failure - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Chronic Heart Failure - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and ...

Peripheral Arterial Disease - Market Insights, Epidemiology and Market Forecast-2023

Peripheral Arterial Disease - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s Peripheral Arterial Disease - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Peripheral Arterial ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.